A New Therapeutic Approach

How It Works
Our formulation chemistry has enabled us to isolate the S-enantiomer of bupropion. This novel formulation is supported through our success at isolating the S-enantiomer of bupropion into dosage forms that maintain their chirality. This compares to our AXS-05 product candidate that contains racemic bupropion (equal amounts of the S– and R-enantiomers). We believe that the individual enantiomers of bupropion may each have unique properties that render them potentially useful in different indications.

Learn more about our science

A Phase 1 study was conducted with AXS-09 that demonstrated a substantial increase in dextromethorphan plasma concentrations to a potentially therapeutic level. Results of this phase 1 trial coupled with preclinical data also indicate the potential for enhanced absorption and therapeutic effect of the S-enantiomer as compared to the R-enantiomer.

Product Pipeline